Cargando…

Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy

Background: Treatment of breast cancer (BC) includes locoregional and systemic therapies depending on tumor and patient’s characteristics. Inositol hexaphosphate (IP6) is known as a strong antioxidant agent, able to improve local (i.e., breast region) side effects, functional status and quality-of-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Amabile, Maria Ida, De Luca, Alessandro, Tripodi, Domenico, D’Alberti, Elena, Melcarne, Rossella, Imbimbo, Giovanni, Picconi, Orietta, D’Andrea, Vito, Vergine, Massimo, Sorrenti, Salvatore, Molfino, Alessio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400775/
https://www.ncbi.nlm.nih.gov/pubmed/34442400
http://dx.doi.org/10.3390/jpm11080756
_version_ 1783745394631507968
author Amabile, Maria Ida
De Luca, Alessandro
Tripodi, Domenico
D’Alberti, Elena
Melcarne, Rossella
Imbimbo, Giovanni
Picconi, Orietta
D’Andrea, Vito
Vergine, Massimo
Sorrenti, Salvatore
Molfino, Alessio
author_facet Amabile, Maria Ida
De Luca, Alessandro
Tripodi, Domenico
D’Alberti, Elena
Melcarne, Rossella
Imbimbo, Giovanni
Picconi, Orietta
D’Andrea, Vito
Vergine, Massimo
Sorrenti, Salvatore
Molfino, Alessio
author_sort Amabile, Maria Ida
collection PubMed
description Background: Treatment of breast cancer (BC) includes locoregional and systemic therapies depending on tumor and patient’s characteristics. Inositol hexaphosphate (IP6) is known as a strong antioxidant agent, able to improve local (i.e., breast region) side effects, functional status and quality-of-life. We investigated some potential beneficial effects, including hematological and local, of the combined therapy with oral myo-inositol administration and topical IP6 application in patients undergoing surgery for BC and eligible to adjuvant chemotherapy. Methods: We considered BC patients randomly assigned to the Inositol Group (oral myo-inositol + IP6 local application for the entire neoadjuvant treatment period) and to the Control Group (standard of care). The EORTC QLQ-BR23 and QLQ-C30 questionnaires were administered to both groups and blood parameters were assessed as per clinical routine practice at baseline (before starting adjuvant chemotherapy), T1 (after the first two doses of epirubicin-cyclophosphamide regimen), T2 (at the end of epirubicin-cyclophosphamide regimen), T3 (after the first six doses of paclitaxel regimen), and T4 (at the end of the paclitaxel treatment). Results: A total of 36 BC patients were considered, 18 in the Inositol Group and 18 in the Control Group. The Inositol Group showed a lower decrease in red blood cells, hemoglobin levels and white blood cells with respect to controls (p ≤ 0.02), as well as amelioration in scores related to breast and arm local symptoms (p ≤ 0.02), body image (p = 0.04) and quality-of-life related symptoms (p ≤ 0.04). Conclusions: In our cohort of BC patients, a combined treatment with oral myo-inositol + IP6 local application was able to improve local symptoms and quality-of-life related symptoms which represent clinically relevant aspects associated with patient’s prognosis.
format Online
Article
Text
id pubmed-8400775
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84007752021-08-29 Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy Amabile, Maria Ida De Luca, Alessandro Tripodi, Domenico D’Alberti, Elena Melcarne, Rossella Imbimbo, Giovanni Picconi, Orietta D’Andrea, Vito Vergine, Massimo Sorrenti, Salvatore Molfino, Alessio J Pers Med Article Background: Treatment of breast cancer (BC) includes locoregional and systemic therapies depending on tumor and patient’s characteristics. Inositol hexaphosphate (IP6) is known as a strong antioxidant agent, able to improve local (i.e., breast region) side effects, functional status and quality-of-life. We investigated some potential beneficial effects, including hematological and local, of the combined therapy with oral myo-inositol administration and topical IP6 application in patients undergoing surgery for BC and eligible to adjuvant chemotherapy. Methods: We considered BC patients randomly assigned to the Inositol Group (oral myo-inositol + IP6 local application for the entire neoadjuvant treatment period) and to the Control Group (standard of care). The EORTC QLQ-BR23 and QLQ-C30 questionnaires were administered to both groups and blood parameters were assessed as per clinical routine practice at baseline (before starting adjuvant chemotherapy), T1 (after the first two doses of epirubicin-cyclophosphamide regimen), T2 (at the end of epirubicin-cyclophosphamide regimen), T3 (after the first six doses of paclitaxel regimen), and T4 (at the end of the paclitaxel treatment). Results: A total of 36 BC patients were considered, 18 in the Inositol Group and 18 in the Control Group. The Inositol Group showed a lower decrease in red blood cells, hemoglobin levels and white blood cells with respect to controls (p ≤ 0.02), as well as amelioration in scores related to breast and arm local symptoms (p ≤ 0.02), body image (p = 0.04) and quality-of-life related symptoms (p ≤ 0.04). Conclusions: In our cohort of BC patients, a combined treatment with oral myo-inositol + IP6 local application was able to improve local symptoms and quality-of-life related symptoms which represent clinically relevant aspects associated with patient’s prognosis. MDPI 2021-07-30 /pmc/articles/PMC8400775/ /pubmed/34442400 http://dx.doi.org/10.3390/jpm11080756 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Amabile, Maria Ida
De Luca, Alessandro
Tripodi, Domenico
D’Alberti, Elena
Melcarne, Rossella
Imbimbo, Giovanni
Picconi, Orietta
D’Andrea, Vito
Vergine, Massimo
Sorrenti, Salvatore
Molfino, Alessio
Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy
title Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy
title_full Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy
title_fullStr Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy
title_full_unstemmed Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy
title_short Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy
title_sort effects of inositol hexaphosphate and myo-inositol administration in breast cancer patients during adjuvant chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400775/
https://www.ncbi.nlm.nih.gov/pubmed/34442400
http://dx.doi.org/10.3390/jpm11080756
work_keys_str_mv AT amabilemariaida effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy
AT delucaalessandro effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy
AT tripodidomenico effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy
AT dalbertielena effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy
AT melcarnerossella effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy
AT imbimbogiovanni effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy
AT picconiorietta effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy
AT dandreavito effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy
AT verginemassimo effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy
AT sorrentisalvatore effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy
AT molfinoalessio effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy